# Weight Loss, Metabolic Health, and Psychiatric Safety > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/semaglutide-for-schizophrenia-weight-gain/ > **Published:** 2026-06-03T19:39:32-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:53:17-04:00 > **Clinical Summary:** Semaglutide for schizophrenia weight gain shows major weight and HbA1c benefits without clear psychiatric worsening, but GI risks need monitoring --- ## Semaglutide for Schizophrenia: Weight Loss Without Psychiatric Risk GLP-1 Receptor Agonists Schizophrenia Spectrum Disorders Antipsychotic-Associated Weight Gain [Metabolic Health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/) Meta-Analysis ## What You Will Learn - How much body weight and BMI semaglutide reduced in patients with schizophrenia spectrum disorders across three placebo-controlled RCTs - Which glycaemic markers improved, and with what degree of evidence certainty - What gastrointestinal adverse events occurred, and why they carry particular clinical weight in this population - Why the absence of psychiatric deterioration signals is clinically meaningful, and what the evidence still cannot tell us **TL;DR: In a pooled analysis of three placebo-controlled RCTs (n = 258), semaglutide produced a mean body-weight reduction of 11.32 kg in adults with schizophrenia spectrum disorders on antipsychotics, with high-certainty evidence and no signal for worsened psychosis or serious adverse events.** ◎ [Systematic Review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) & Meta-Analysis of Randomised Controlled Trials ## Abstract **Background:** People with schizophrenia spectrum disorders (SSDs) experience high rates of obesity and metabolic dysfunction, contributing substantially to excess morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide have demonstrated substantial efficacy for weight and glycaemic outcomes in the general population, but evidence in people with SSDs remains limited. **Aims:** To synthesise all placebo-controlled, randomised controlled trials examining semaglutide and/or tirzepatide in people with SSDs. **Method:** A preregistered systematic review and meta-analysis of RCTs examining the efficacy and safety of semaglutide and/or tirzepatide in adults with SSDs was conducted. Outcomes and adverse events were pooled using random-effects meta-analysis. Certainty of evidence was assessed using the GRADE criteria. **Results:** Three trials (n = 258) met inclusion criteria, examining semaglutide dosages of 1.0 to 2.0 mg over 26 to 36 weeks. No trials examining tirzepatide were found. Semaglutide significantly reduced body weight (−11.32 kg; 95% CI −15.35 to −7.29), body mass index (−3.58 kg/m²; 95% CI −4.86 to −2.30), haemoglobin A1c (−0.37%; 95% CI −0.51 to −0.22) and fasting glucose (−0.54 mmol/L; 95% CI −0.94 to −0.13). In adverse event analyses, semaglutide was associated with increased risks of abdominal pain (risk ratio 2.93; 95% CI 1.13 to 7.60), vomiting (risk ratio 2.57; 95% CI 1.39 to 4.77) and constipation (risk ratio 3.23; 95% CI 1.14 to 9.18). There was no evidence of increased risk of serious adverse events. **Conclusions:** Semaglutide produces clinically meaningful improvements in weight and glycaemic outcomes in people with SSDs, with an adverse event profile consistent with known gastrointestinal effects of GLP-1 RAs in the general population. These findings support semaglutide as a promising adjunctive metabolic intervention in this population, although larger and longer trials, specifically those testing tirzepatide, are needed to better characterise heterogeneity of effects and long-term safety. **Source:** Trott M, Arnautovska U, Johnston D, Ritchie G, Siskind D. The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. *BJPsych Open.* 2026;12:e147. **DOI:** [10.1192/bjo.2026.12001](https://doi.org/10.1192/bjo.2026.12001) **Open Access:** Creative Commons Attribution 4.0 License ## Study at a Glance Design Preregistered systematic review and random-effects meta-analysis of placebo-controlled RCTs (PROSPERO: CRD420251247162) Population Adults with schizophrenia, schizoaffective disorder, or schizotypal disorder per ICD-10 or DSM criteria, receiving antipsychotic medications Sample Size 258 participants across 3 RCTs Intervention Semaglutide 1.0 mg (two trials) or 2.0 mg (one trial), weekly subcutaneous injection, 26 to 36 weeks Comparator Placebo Primary Finding Semaglutide reduced body weight by a mean of 11.32 kg (95% CI −15.35 to −7.29; high certainty) and BMI by 3.58 kg/m² (95% CI −4.86 to −2.30; high certainty), with no increased risk of serious adverse events ## Study Snapshot: Key Statistics Outcome Treatment Effect 95% CI p-value GRADE Certainty Body weight (kg) −11.32 kg −15.35 to −7.29 <0.001 High BMI (kg/m²) −3.58 −4.86 to −2.30 <0.001 High HbA1c (%) −0.37% −0.51 to −0.22 <0.001 High Fasting glucose (mmol/L) −0.54 −0.94 to −0.13 0.01 Moderate Systolic BP (mmHg) −2.34 −5.53 to 0.84 0.149 Low Diastolic BP (mmHg) −0.39 −2.83 to 2.06 0.756 Low Fasting insulin (mU/L) −3.03 −7.98 to 1.93 0.231 Very low Fasting triglycerides (mmol/L) −0.14 −0.41 to 0.13 0.305 Very low HDL cholesterol (mmol/L) +0.07 −0.10 to 0.24 0.434 Very low Abdominal pain (RR) 2.93 1.13 to 7.60 0.027 High Vomiting (RR) 2.57 1.39 to 4.77 0.003 High Constipation (RR) 3.23 1.14 to 9.18 0.028 Moderate Serious adverse events (RR) 0.81 0.52 to 1.26 0.345 Low RR = risk ratio; BP = blood pressure; HbA1c = haemoglobin A1c; HDL = high-density lipoprotein. AE rows shaded. All effects are semaglutide versus placebo. ## Study Facts Authors Mike Trott, Urska Arnautovska, Donni Johnston, Gabrielle Ritchie, Dan Siskind Journal *BJPsych Open* Year 2026 DOI 10.1192/bjo.2026.12001 Study Design Preregistered systematic review and random-effects meta-analysis of placebo-controlled RCTs PROSPERO Registration CRD420251247162 (registered 9 December 2025) Number of Trials 3 RCTs Total N 258 participants Population Adults with schizophrenia spectrum disorders (schizophrenia, schizoaffective disorder, schizotypal disorder) on antipsychotic therapy; predominantly on clozapine or olanzapine Intervention Semaglutide 1.0 mg/week (two trials) or 2.0 mg/week (one trial), subcutaneous, for 26 to 36 weeks Comparator Placebo Primary Endpoint (review-defined) Efficacy and safety outcomes including body weight, BMI, glycaemic markers, and adverse events Key Efficacy Results Body weight: −11.32 kg (95% CI −15.35 to −7.29; p <0.001; high certainty); BMI: −3.58 kg/m² (95% CI −4.86 to −2.30; p <0.001; high certainty); HbA1c: −0.37% (95% CI −0.51 to −0.22; p <0.001; high certainty); fasting glucose: −0.54 mmol/L (95% CI −0.94 to −0.13; p = 0.01; moderate certainty) Key Safety Results Abdominal pain RR 2.93 (95% CI 1.13 to 7.60); vomiting RR 2.57 (95% CI 1.39 to 4.77); constipation RR 3.23 (95% CI 1.14 to 9.18); serious adverse events RR 0.81 (95% CI 0.52 to 1.26, non-significant) Risk of Bias All three component trials rated low risk of bias (Cochrane RoB2 tool) Funding No specific grant from any funding agency, commercial or not-for-profit Conflicts of Interest D. Siskind was a member of the BJPsych Editorial Board but did not participate in review or decision-making for this paper. All other authors declared no conflicts. ## What Researchers Actually Did Trott and colleagues conducted a preregistered systematic review and meta-analysis, searching PubMed, EMBASE, PsycINFO, Scopus, and CENTRAL on 6 December 2025. Their inclusion criteria were narrow and explicit: placebo-controlled RCTs of semaglutide or tirzepatide in adults with a formal SSD diagnosis, with no restriction on dosage, duration, or outcome. Two independent reviewers handled screening, full-text assessment, and data extraction at every stage; agreement was 100% throughout, and no arbitration was required. Risk of bias was assessed with the Cochrane RoB2 tool. Three trials met criteria, all examining semaglutide: Ganeshalingam et al. (n = 154, 1 mg, 30 weeks, Denmark), Sass et al. (n = 73, 1 mg, 26 weeks, Denmark), and Siskind et al. (n = 31, 2 mg, 36 weeks, Australia). No tirzepatide trials were identified. Statistical pooling used a random-effects framework with restricted maximum likelihood estimation; heterogeneity was quantified with τ², and prediction intervals were calculated alongside point estimates. Continuous outcomes required at least three contributing studies to enter the meta-analysis; fewer than three were narratively synthesised. Adverse events were pooled as risk ratios after log-transformation, using the same random-effects method. Evidence certainty was graded with GRADE. Publication bias was not formally assessed because the pool contained fewer than ten studies. ## Key Findings: Primary Outcomes - **Body weight:** Semaglutide reduced weight by a mean of 11.32 kg (95% CI −15.35 to −7.29 kg; p <0.001; τ² = 10.15; prediction interval −18.75 to −3.89 kg; GRADE high certainty). - **BMI:** Mean reduction of 3.58 kg/m² (95% CI −4.86 to −2.30; p <0.001; τ² = 1.00; prediction interval −5.93 to −1.24 kg/m²; GRADE high certainty). - **HbA1c:** Mean reduction of 0.37% (95% CI −0.51 to −0.22; p <0.001; τ² = 0.01; prediction interval −0.62 to −0.11%; GRADE high certainty). - **Fasting glucose:** Mean reduction of 0.54 mmol/L (95% CI −0.94 to −0.13; p = 0.01; τ² = 0.09; prediction interval −1.26 to 0.19 mmol/L; GRADE moderate certainty). - The authors note that the 11% reduction in body weight was achieved at semaglutide doses of 1.0 to 2.0 mg over 26 to 36 weeks, compared with the 2.4 mg dose used over 68 weeks in the Wilding et al. STEP 1 general-population trial, which yielded approximately 15% weight loss. ## Key Findings: Secondary Outcomes No outcomes other than those listed above reached statistical significance in the pooled meta-analysis. Several narratively synthesised outcomes showed directionally consistent but non-significant patterns: - **Body composition:** Significant reductions in body fat percentage, waist circumference, and visceral fat were reported across the two trials measuring these outcomes; hip circumference decreased significantly in Ganeshalingam et al. Waist-to-hip ratio and bone mineral content showed no significant change in any trial. - **Insulin resistance:** Two studies reported consistent decreases, but neither reached statistical significance. - **Lipids:** Consistent non-significant reductions in triglycerides and heart rate; non-significant and conflicting effects for LDL and total cholesterol. - **Blood pressure:** Systolic BP: −2.34 mmHg (95% CI −5.53 to 0.84; not significant; low certainty). Diastolic BP: −0.39 mmHg (not significant; low certainty). - **Psychiatric symptom severity:** PANSS total, PANSS subscales, CGI-S, and most cognitive domains (BACS) showed non-significant or conflicting results. No consistent signal of clinical deterioration was observed across any trial. - **Clozapine and norclozapine concentrations:** No significant or consistent changes reported by Siskind et al., suggesting absence of pharmacokinetic interaction in that sample. - **Nicotine dependence:** A significant reduction on the Fagerström Test for Nicotine Dependence was reported by Sass et al. (single study; not meta-analysed). - **BACS verbal memory learning:** Siskind et al. reported a significant increase, but this was an isolated finding from a single small trial and should be interpreted with considerable caution. No formal subgroup analyses by antipsychotic class, baseline metabolic status, or demographic variables were reported or feasible given the three-trial evidence base. ## Adverse Events and Safety Profile Six adverse event categories contained sufficient data for meta-analysis. Three showed statistically significant elevations in the semaglutide group: - **Abdominal pain:** RR 2.93 (95% CI 1.13 to 7.60; p = 0.027; τ² = 0; prediction interval 1.13 to 7.60; GRADE high certainty) - **Vomiting:** RR 2.57 (95% CI 1.39 to 4.77; p = 0.003; τ² = 0; prediction interval 1.39 to 4.77; GRADE high certainty) - **Constipation:** RR 3.23 (95% CI 1.14 to 9.18; p = 0.028; τ² = 0.38; prediction interval 0.65 to 16.03; GRADE moderate certainty) Three categories did not differ significantly between groups: - **Diarrhoea:** RR 1.50 (95% CI 0.69 to 3.24; not significant; low certainty) - **Nausea:** RR 1.44 (95% CI 0.87 to 2.39; not significant; low certainty) - **Serious adverse events:** RR 0.81 (95% CI 0.52 to 1.26; not significant; low certainty) Non-meta-analysed adverse events, including psychiatric admissions, self-harm, suicidal behaviour, neurological symptoms (dizziness, fatigue, headache), and infections, were infrequently and inconsistently reported across trials, with no consistent pattern of increased risk. Rates of any adverse event and adverse events leading to discontinuation were broadly comparable between groups, with risk ratios close to unity where reported. The timing of adverse events relative to dose escalation was not reported in any component study, a gap the authors identify as clinically important. ## Statistical Approach and Rigor The analytic strategy was appropriate for the available data. Random-effects pooling with restricted maximum likelihood estimation is the correct default when between-study heterogeneity is expected, and the authors provided prediction intervals alongside point estimates, which is a more informative and honest representation of effect variability than confidence intervals alone. The weight prediction interval of −18.75 to −3.89 kg, for example, captures the plausible range of effects across settings, not merely the uncertainty around the average. GRADE was applied systematically to rate certainty. Risk-of-bias assessment used the Cochrane RoB2 tool with dual independent reviewers and 100% agreement. All three component trials were rated low risk of bias. Two methodological constraints bear emphasis. First, with only three contributing studies, heterogeneity estimates (τ²) are themselves imprecise; the pooled τ² for body weight of 10.15 suggests meaningful between-study variability, and the prediction interval should temper confidence in the point estimate for any specific [clinical context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/). Second, publication bias could not be formally assessed with fewer than ten studies. Given that three ongoing trials were identified but had not yet published results, selective reporting of positive findings cannot be excluded. The authors correctly note this constraint. ## Clinical Takeaway For clinicians managing adults with schizophrenia spectrum disorders whose weight has risen substantially on clozapine or olanzapine, this meta-analysis provides the most consolidated RCT evidence to date that semaglutide produces a clinically meaningful reduction in body weight and improves glycaemic markers, without worsening psychiatric symptom severity or generating a signal for serious adverse events. The gastrointestinal adverse event profile, particularly abdominal pain, vomiting, and constipation, is real and requires anticipatory management. In patients receiving clozapine, where constipation independently carries serious risk, this overlap demands careful attention: slow dose titration, proactive bowel regimen, hydration monitoring, and early follow-up are not optional adjuncts but obligatory safeguards. The evidence does not yet extend to tirzepatide, longer durations, or hard cardiovascular endpoints. **Clinical Bottom Line: Semaglutide at 1.0 to 2.0 mg produced high-certainty, double-digit kilogram weight loss in adults with schizophrenia spectrum disorders without psychiatric deterioration, but the evidence base is three small trials, gastrointestinal adverse events are near-tripled in risk, and no data yet exist beyond 36 weeks or for tirzepatide.** ## Why This Matters Clinically People with schizophrenia spectrum disorders die 10 to 20 years earlier than the general population, and the majority of those premature deaths are attributable to cardiovascular and metabolic disease, not to the psychiatric disorder itself. Antipsychotic medications, particularly clozapine and olanzapine, accelerate metabolic risk through mechanisms that include weight gain, dyslipidaemia, and dysglycaemia. The prior standard pharmacological adjunct, metformin, produces roughly 3 kg of weight loss relative to placebo in this population. Semaglutide, at lower doses and shorter durations than general-population obesity trials, appears to generate three to four times that effect. That magnitude, if durable and translatable to cardiovascular outcomes, has the potential to materially alter life expectancy trajectories in a population historically underserved by metabolic medicine. The simultaneous absence of psychosis worsening and pharmacokinetic interaction with clozapine (at least in one trial) removes what had been a reasonable theoretical concern about GLP-1 agonism in a dopaminergically vulnerable population. ## CED Clinical Relevance At CED Clinic, we frequently evaluate patients whose psychiatric pharmacotherapy has generated substantial metabolic burden, including obesity, pre-diabetes, and dyslipidaemia. Many of these patients are already managing complex polypharmacy and have had limited success with behavioural interventions alone. This meta-analysis is directly relevant to that clinical scenario. The evidence now supports a structured, monitored trial of semaglutide as an adjunctive strategy, particularly in patients on clozapine or olanzapine with BMI at or above 27 kg/m² and evidence of dysglyca Evidence Watch Reading Tool ### Read This Paper Through Nine Different Lenses The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks. OVERVIEW Semaglutide significantly reduced body weight and BMI in SSDs with no increased risk of psychiatric deterioration. #### Overview Badge 1: High EfficacyBadge 2: No Psychiatric RiskBadge 3: Gastrointestinal [Side Effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) Semaglutide significantly reduced body weight and BMI in adults with schizophrenia spectrum disorders, demonstrating high efficacy without worsening psychiatric symptoms. However, it was associated with increased risks of gastrointestinal adverse events such as abdominal pain, vomiting, and constipation. - Semaglutide produced a mean body-weight reduction of 11.32 kg. - No evidence of increased risk of serious adverse events or worsened psychosis was observed. - Gastrointestinal side effects were notable but manageable. Key Insight Semaglutide effectively reduces weight in schizophrenia spectrum disorders without worsening psychiatric symptoms. #### Patient Takeaway Badge 1: Weight LossBadge 2: Improved MetabolismBadge 3: Gastrointestinal Side Effects Patients with schizophrenia spectrum disorders can benefit from semaglutide, which helps in reducing body weight and improving metabolic markers like HbA1c and fasting glucose. However, they may experience gastrointestinal side effects such as abdominal pain and vomiting. - Semaglutide reduces body weight by 11.32 kg on average. - Metabolic health improves with reductions in HbA1c and fasting glucose. - Gastrointestinal adverse events like abdominal pain and vomiting are common but manageable. Patient Takeaway Semaglutide can help manage weight and metabolic issues without worsening psychiatric symptoms. #### Clinician’s POV Badge 1: High EfficacyBadge 2: No Psychiatric RiskBadge 3: Gastrointestinal Side Effects Clinicians can consider semaglutide as a safe and effective treatment for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) in patients with schizophrenia spectrum disorders. While it reduces body weight and improves metabolic health, clinicians should monitor for gastrointestinal side effects. - Semaglutide significantly reduced body weight by 11.32 kg. - No increased risk of serious adverse events or worsened psychosis was observed. - Gastrointestinal side effects such as abdominal pain and vomiting were noted. Clinician Takeaway Semaglutide is effective for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) in SSDs without worsening psychiatric symptoms. #### A Skeptical Read Badge 1: Small Sample SizeBadge 2: Limited Data on TirzepatideBadge 3: Gastrointestinal Side Effects While semaglutide shows promise, the study’s small sample size and limited data on tirzepatide raise questions about its broader applicability. Additionally, gastrointestinal side effects are a concern that needs further investigation. - The study included only 258 participants across three trials. - No tirzepatide trials were identified for analysis. - Gastrointestinal adverse events such as abdominal pain and vomiting were common. Skeptic Takeaway Semaglutide shows promise but requires further research due to small sample size and gastrointestinal side effects. #### Study Critic Badge 1: High EfficacyBadge 2: No Psychiatric RiskBadge 3: Limited Long-Term Data Critics may argue that while semaglutide is effective and safe in the short term, long-term data are lacking. The study’s focus on a small number of trials also limits its generalizability. - Semaglutide reduced body weight by 11.32 kg with high efficacy. - No increased risk of serious adverse events or worsened psychosis was observed. - Long-term safety and efficacy data are needed for broader application. Critic Takeaway Semaglutide is effective but long-term safety and efficacy need further study. #### Compared to Past Research Badge 1: Previous ResearchBadge 2: Antipsychotic-Associated Weight GainBadge 3: Metabolic Health Concerns Prior research has highlighted the challenges of antipsychotic-associated weight gain and metabolic health issues in schizophrenia spectrum disorders. Semaglutide offers a promising approach to address these concerns. - Antipsychotics are associated with significant weight gain. - Metabolic health is a critical concern for patients with SSDs. - Semaglutide addresses both weight management and metabolic health. Historical Context Previous research underscores the need for effective treatments to manage weight and metabolic issues in SSDs. #### Practical Considerations Badge 1: Practical ApplicationBadge 2: Monitoring Gastrointestinal Side EffectsBadge 3: Integration with Antipsychotic Therapy Practically, semaglutide can be integrated into the treatment regimen of patients on antipsychotics to manage weight and metabolic health. Clinicians should monitor for gastrointestinal side effects and adjust dosages as needed. - Semaglutide can be used alongside antipsychotic therapy. - Monitoring for gastrointestinal adverse events is crucial. - Dosage adjustments may be necessary based on individual patient response. Practical Advice Integrate semaglutide into treatment plans while monitoring for gastrointestinal side effects. #### Future Directions Badge 1: Larger Trials NeededBadge 2: Tirzepatide ResearchBadge 3: Long-Term Safety Future research should focus on larger and longer trials to better understand the long-term safety and efficacy of semaglutide. Additionally, studies on tirzepatide in schizophrenia spectrum disorders are needed to compare its effects. - Larger and longer trials are required for comprehensive understanding. - Research on tirzepatide is necessary for comparison. - Long-term safety and efficacy need further investigation. Future Directions Further research is needed to explore long-term safety and efficacy of semaglutide in SSDs. #### Misreadings & Bad-Faith Takes Badge 1: Misinterpretation RiskBadge 2: Overlooking Psychiatric SafetyBadge 3: Ignoring Side Effects Misreadings of this study might overlook the psychiatric safety of semaglutide or ignore gastrointestinal side effects. It is crucial to understand that while effective, semaglutide does not worsen psychiatric symptoms and requires monitoring for adverse events. - Misinterpretations may overlook psychiatric safety. - Gastrointestinal side effects should not be ignored. - Comprehensive understanding of benefits and risks is essential. Avoid Misreadings Understand that semaglutide is safe for psychiatric symptoms but requires monitoring for gastrointestinal side effects. Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=The%20safety%20and%20efficacy%20of%20semaglutide%20in%20people%20with%20schizophrenia%20spectrum%20dis&url=https%3A%2F%2Fcedclinic.com%2Fthe-safety-and-efficacy-of-semaglutide-in-people-with-schizophrenia-spectrum-dis%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fthe-safety-and-efficacy-of-semaglutide-in-people-with-schizophrenia-spectrum-dis%2F) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=The%20safety%20and%20efficacy%20of%20semaglutide%20in%20people%20with%20schizophrenia%20spectrum%20dis%20https%3A%2F%2Fcedclinic.com%2Fthe-safety-and-efficacy-of-semaglutide-in-people-with-schizophrenia-spectrum-dis%2F) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/) [🔔 Subscribe via RSS](https://cedclinic.com/feed/) RELATED READING AT CED CLINIC Continue exploring the evidence [How CED Clinic Approaches Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework. [Explore evidence](https://cedclinic.com/metabolic/metabolic-how-it-works/) [GLP-1 Medications and Weight Loss: What Patients Need to Know](https://cedclinic.com/glp-1-weight-loss-access-clinical-evidence/) A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice. [Read article](https://cedclinic.com/glp-1-weight-loss-access-clinical-evidence/) [Cannabis for Pain Management: Matching Products to Symptoms](https://cedclinic.com/cannabis-for-pain-relief/) A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns. [Continue reading](https://cedclinic.com/cannabis-for-pain-relief/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### What is semaglutide and how does it work? Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that mimics the effects of GLP-1, a hormone that helps regulate blood sugar levels and promotes weight loss. ### How effective is semaglutide in reducing body weight for people with schizophrenia spectrum disorders? Semaglutide produced a mean body-weight reduction of 11.32 kg in adults with schizophrenia spectrum disorders on antipsychotics. ### Does semaglutide improve glycemic markers in people with schizophrenia? Semaglutide significantly reduced haemoglobin A1c by 0.37% and fasting glucose by 0.54 mmol/L. ### What are the gastrointestinal adverse events associated with semaglutide? Semaglutide was associated with increased risks of abdominal pain, vomiting, and constipation. ### Is there a risk of psychiatric deterioration with semaglutide use in schizophrenia spectrum disorders? No evidence of increased risk of serious adverse events or worsened psychosis was observed. ### How does the study’s sample size and duration compare to other weight loss studies? The study included 258 participants over 26 to 36 weeks, which is smaller than some general population trials. ### What are the implications of these findings for clinical practice? These findings support semaglutide as a promising adjunctive metabolic intervention in people with schizophrenia spectrum disorders. ### Are there any limitations to this study? The study is limited by the small number of trials and participants, and further research on tirzepatide is needed. ### What are the next steps in research for semaglutide in schizophrenia spectrum disorders? Larger and longer trials, specifically those testing tirzepatide, are needed to better characterize heterogeneity of effects and long-term safety. ### How does this study contribute to the understanding of metabolic health in schizophrenia? This study highlights the potential for GLP-1 RAs to improve metabolic health without worsening psychiatric symptoms in people with schizophrenia spectrum disorders. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).